CN109077326A - A kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing - Google Patents
A kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing Download PDFInfo
- Publication number
- CN109077326A CN109077326A CN201810464630.2A CN201810464630A CN109077326A CN 109077326 A CN109077326 A CN 109077326A CN 201810464630 A CN201810464630 A CN 201810464630A CN 109077326 A CN109077326 A CN 109077326A
- Authority
- CN
- China
- Prior art keywords
- powder
- vitamin
- bone collagen
- mouse
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 28
- 108010035532 Collagen Proteins 0.000 title claims abstract description 28
- 229920001436 collagen Polymers 0.000 title claims abstract description 28
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 19
- 230000000694 effects Effects 0.000 title abstract description 24
- 230000036039 immunity Effects 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 76
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 244000078534 Vaccinium myrtillus Species 0.000 claims abstract description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 12
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 241000193749 Bacillus coagulans Species 0.000 claims abstract description 8
- 229940054340 bacillus coagulans Drugs 0.000 claims abstract description 8
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 7
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 7
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 7
- 239000005862 Whey Substances 0.000 claims abstract description 7
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 7
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 7
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims abstract description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 244000298697 Actinidia deliciosa Species 0.000 claims abstract description 6
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims abstract description 6
- 241000167854 Bourreria succulenta Species 0.000 claims abstract description 6
- 244000276331 Citrus maxima Species 0.000 claims abstract description 6
- 235000001759 Citrus maxima Nutrition 0.000 claims abstract description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 6
- 229920001202 Inulin Polymers 0.000 claims abstract description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 240000007651 Rubus glaucus Species 0.000 claims abstract description 6
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 6
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 6
- 244000269722 Thea sinensis Species 0.000 claims abstract description 6
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 6
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 6
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 6
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 6
- 235000020279 black tea Nutrition 0.000 claims abstract description 6
- 235000021014 blueberries Nutrition 0.000 claims abstract description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract description 6
- 235000019693 cherries Nutrition 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 claims abstract description 6
- 229960002413 ferric citrate Drugs 0.000 claims abstract description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 6
- 235000012907 honey Nutrition 0.000 claims abstract description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 6
- 229940029339 inulin Drugs 0.000 claims abstract description 6
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims abstract description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 6
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 6
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 6
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 6
- 235000019871 vegetable fat Nutrition 0.000 claims abstract description 6
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 6
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 6
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 240000001890 Ribes hudsonianum Species 0.000 claims abstract description 5
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims abstract description 5
- 235000001466 Ribes nigrum Nutrition 0.000 claims abstract description 5
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims abstract description 5
- 244000291414 Vaccinium oxycoccus Species 0.000 claims abstract description 5
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims abstract description 5
- 235000004634 cranberry Nutrition 0.000 claims abstract description 5
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 5
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 229940083542 sodium Drugs 0.000 claims abstract 2
- 239000011812 mixed powder Substances 0.000 claims description 7
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 235000021028 berry Nutrition 0.000 claims description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- 229930003471 Vitamin B2 Natural products 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 26
- 210000000822 natural killer cell Anatomy 0.000 abstract description 11
- 230000036737 immune function Effects 0.000 abstract description 10
- 210000002540 macrophage Anatomy 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 43
- 239000013642 negative control Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 235000012054 meals Nutrition 0.000 description 10
- 241000143060 Americamysis bahia Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 244000046052 Phaseolus vulgaris Species 0.000 description 9
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 9
- 235000013622 meat product Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000000242 pagocytic effect Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 235000013311 vegetables Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 240000007594 Oryza sativa Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000003024 peritoneal macrophage Anatomy 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 230000007306 turnover Effects 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 208000020442 loss of weight Diseases 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 206010016352 Feeling of relaxation Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000020983 fruit intake Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000020903 low-carbon-diet Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000000955 splenic vein Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004367 thymic lymphocyte Anatomy 0.000 description 1
- 230000005313 thymus development Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a kind of bone collagen compound powder, mainly by bone collagen Gly-His-Lys, PURE WHEY, skimmed milk powder, vegetable fat powder, D-sorbite, inulin, oligofructose, calcium monohydrogen phosphate, instant black tea, xylo-oligosaccharide, Cranberry powder, blueberry powder, blackberry powder, raspberry powder, cherry powder, honey peach powder, blackcurrant powder, kiwi fruit powder, shaddock powder, orange powder, essence for food, γ-aminobutyric acid, L-AA sodium, bacillus coagulans, zinc gluconate, ferric citrate, niacin, pantothenic acid, vitamin B1, vitamin B2, vitamin B6, vitamin composition.Resulting composition is negative to mouse cell immune function, humoral immune function is positive, single unification macrophage function is positive, NK cell activity is positive, determines that the composition has enhancing immunity function, while having apparent fat-reducing effect.
Description
Technical field
The present invention relates to field of health care food, and in particular to a kind of collagen peptide combinations.
Background technique
With the promotion of living standard, the accelerating rhythm of life, the quantity of population of being obese is increasingly soaring, and consequent is just
It is the increase of various rich people's disease illness probabilities, therefore, how guides people to improve diet structure, how to guarantee nutrition balanced and reasonable
At extremely urgent task.
Low-carbon diet is exactly a kind of good diet solution, and core is to control the intake of carbohydrate, from
And by human body from the metabolic conversion of carbohydrate is consumed at the metabolic patterns based on consumption fat.Though carbohydrate is people
The main source of body heat content, and cause fat reason.Since carbohydrate is decomposed into after blood, internal pancreas can be enabled
Island element is soaring, and accelerated decomposition is monosaccharide, energy supply needed for providing physical activity.But if body is when having enough power, just
It can be converted into fatty storage, in case this to form fat probability with regard to increasing naturally needed in the future.For because intake is excessive
Carbohydrate and for the people of obesity, if applying this weight reduction according to balanced nutritious principle, can receive apparent
Weight reduction effect.
Excessive carbohydrate will cause obesity really, if but therefore refuse carbohydrate comprehensively, may but it cause
Other health problems.Therefore, it is necessary to the nutritional interventions of science, that is, pass through the nutrition intake of control people's diet this aspect
Proportion adjusts the composed structure of the nutriment of human body intake with this, guarantees immunity of organisms not by shadow while weight-reducing
It rings.
Summary of the invention
The purpose of the present invention is to provide a kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing.
Bone collagen peptide combinations of the present invention are as made by the raw material of following weight (W/W):
Bone collagen Gly-His-Lys 16%, PURE WHEY 16%, skimmed milk powder 12.8%, vegetable fat powder 16%, D-sorbite
8%, inulin 10%, oligofructose 4.844%, calcium monohydrogen phosphate 3.824%, instant black tea 1.68%, xylo-oligosaccharide 0.8%, climing
More certain kind of berries powder 0.8%, blueberry powder 0.8%, blackberry powder 0.8%, raspberry powder 0.8%, cherry powder 0.8%, honey peach powder 0.8%, black
Gallon powder 0.8%, kiwi fruit powder 0.8%, shaddock powder 0.8%, orange powder 0.8%, essence for food 1.2%, γ-aminobutyric acid
0.3%, L-AA sodium 0.246%, bacillus coagulans 0.2%, zinc gluconate 0.044%, ferric citrate
0.046%, niacin 0.011%, pantothenic acid 0.0022%, vitamin B10.001%, vitamin B20.001%, vitamin
B60.0008%, vitamin D 0.000002%.
Bone collagen peptide combinations of the present invention the preparation method is as follows:
(1) by oligofructose, calcium monohydrogen phosphate, instant black tea, xylo-oligosaccharide, Cranberry powder, blueberry powder, blackberry powder, raspberry
Powder, cherry powder, honey peach powder, blackcurrant powder, kiwi fruit powder, shaddock powder, orange powder, essence for food, γ-aminobutyric acid, L-
Sodium ascorbate, zinc gluconate, ferric citrate, bacillus coagulans, niacin, pantothenic acid (D-VB5 calcium), vitamin B1, dimension
Raw element B2, vitamin B6, vitamin D mix to obtain mixed powder 1；
(2) bone collagen Gly-His-Lys, PURE WHEY, skimmed milk powder, vegetable fat powder, D-sorbite, inulin mixing, must mix
Powder 2；
(3) above-mentioned mixed powder 1,2 is mixed, be uniformly mixed to get.
Bone collagen Gly-His-Lys of the present invention are the bone collagen peptide (TQS169) of day surprise biological production, be can promote
Thymus development, weight, the number of thymic lymphocytes and activity including increasing thymus gland, also can be improved T lymphocyte to there is silk
Divide the reactivity of primary stimuli.The T cell IL-2 of activation generates increase, and the IL-2 receptor on surface also increases, and time of occurrence mentions
Before, to promote the proliferation of T cell, differentiation and maturation.T- cell mediated can be improved in bone collagen peptide (TQS169)
Cellular immune function, including delayed allergy and cytotoxicity.Bone collagen peptide (TQS169) can also enhance monokaryon
Cell and macrophage activity.
Bacillus coagulans of the present invention are bacillus coagulans (U.S. probiotics BC30), can in intestinal colonisation,
Body macrophage activity is activated, immune response is induced；Simultaneously by interacting between itself and its metabolite and other bacteriums, tie up
It holds and guarantees that flora optimal vigor combines, pathogenic bacteria is prevented to be colonized into, antagonism pathogenic bacteria and harmful microorganism growth and its toxin
Absorption；Non-specific and specific immune response, activity of natural killer cell can be improved by activating macrophage, enhance cell
Factor expression is horizontal, promotes the expression of immunoglobulin especially secretory IgA, to play the function of product strengthen immunity
Effect.
Product beneficial effect of the invention is as follows:
(1) negative to mouse cell immune function, the humoral immune function positive, one macrophage function of the monokaryon positive, NK
Cell activity is positive, therefore, it is determined that the given the test agent has strengthen immunity function.
(2) there is apparent fat-reducing effect.
(3) raw material is easy to draw materials simultaneously, formula is reasonable, effect is obvious, moderate, easy to use, has wide city
Field application prospect.
Specific embodiment
Below by specific embodiment, the present invention is described in further detail.
Embodiment 1
Formula:
Preparation method:
(1) by oligofructose, calcium monohydrogen phosphate, instant black tea, xylo-oligosaccharide, Cranberry powder, blueberry powder, blackberry powder, raspberry
Powder, cherry powder, honey peach powder, blackcurrant powder, kiwi fruit powder, shaddock powder, orange powder, essence for food, γ-aminobutyric acid, L-
Sodium ascorbate, zinc gluconate, ferric citrate, bacillus coagulans, niacin, pantothenic acid (D-VB5 calcium), vitamin B1, dimension
Raw element B2, vitamin B6, vitamin D mix to obtain mixed powder 1；
(2) bone collagen Gly-His-Lys, PURE WHEY, skimmed milk powder, vegetable fat powder, D-sorbite, inulin mixing, must mix
Powder 2；
(3) above-mentioned mixed powder 1,2 is mixed, be uniformly mixed to get.
2 bone collagen peptide combinations strengthen immunity function test of embodiment
Laboratory sample: embodiment 1
Experimental animal: female mice in SPF grades of Kunming, 18-22g, 200.
Experimental method:
Dose design and grouping: animal is divided into five experimental groups, every group 40, carries out following five experiments respectively: immune
Test one group of carry out delayed hair allergy experiment；The mouse lymphocyte of two groups of carry out ConAn inductions of immunization experiment converts real
It tests and NK cytoactive detection；Three groups of carry out Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell experiments of immunization experiment；Immunization experiment
The measurement and antibody-producting cell detection of four groups of carry out serum hemolysins；Five groups of carry out lymphoid organ/weight ratios of immunization experiment
Measurement and carbonic clearance experiment.
Every experimental group, which is all provided with, sets low middle high three dosage groups and a negative control group, every group of 10 animals.Human body intake
Amount is 75g/ person/days, i.e. 1.25g/kgBW (presses human body weight 60kg to calculate), and three dosage group intakes are respectively human intaking amount
10,20,30 times, i.e. 12.5g/kgBW, 25g/kgBW, 37.5g/kgBW.
(1) ConA inducing mouse Splenic vein hemodynamics are tested
Using mtt assay.It is sterile to take spleen, it is placed in and fills in appropriate sterile Hank ' s liquid plate, gently ground spleen with tweezers,
Individual cells suspension is made.Through 200 mesh net filtrations, is washed 2 times with Hank ' s liquid, be centrifuged 10min (1000r/min) every time.So
Cell is suspended in the complete culture solution of 1mL afterwards, with platform phenol orchid dyeing counting viable count (should be 95% or more), adjustment is thin
Born of the same parents' concentration is 3 × 106A/mL.It is divided to two holes to be added in 24 holes culture version every a splenocyte suspension, every hole 1mL, a hole adds
5%CO is set as control in 75uL ConA liquid (being equivalent to 7.5ug/mL), another hole2, 37 DEG C of CO272h is cultivated in incubator.Culture
4h before terminating, every hole gently suck supernatant 0.7mL, and the RPMI1640 culture solution that 0.7mL is free of calf serum is added, adds simultaneously
Enter the hole MTT (5mg/mL) 50uL/, continues to cultivate 4h.After culture, 1mL acid isopropyl alcohol is added in every hole, and piping and druming mixes, makes
Purple crystal is completely dissolved.Then it is dispensed into 96 well culture plates, 3 parallel holes (hole 100uL/) is done in each hole, uses microplate reader
OD value is measured with 570nm wavelength.
(2) dinitrofluorobenzene (DNFB) induction delayed allergy (DTH)
Using ear swelling method.After (preparing) sensitized mice with 1: 1 acetone sesame oil solution with 1%DNFB, use again within the 5th day
DNFB attacks auris dextra, puts to death animal afterwards for 24 hours and cuts the auricle that left and right auricular concha removes diameter 8mm with punch, weighs, with left and right ear
The difference of weight indicate the degree of DTH.
(3) antibody-producting cell detection
Jeme improves slide method.The sheep blood of extracting degreasing fiber is centrifuged (2000r/min) every time with brine 3 times
10min, every mouse is through being injected intraperitoneally 2% (v/v) SRBC 0.2mL.Mouse cervical dislocation after SRBC is immunized 4-5 days is put to death,
Spleen is taken out, is placed in the small plate for being loaded with Hank ' s liquid, is lightly ground spleen, cell suspension is made, through 200 mesh screen mistakes
Filter,
It is centrifuged 10min (1000r/min), is washed 2 times with Hank ' s liquid, cell is finally suspended in 5mL RPMI1640 culture
In liquid, cell is counted, and cell concentration is adjusted to 5 × 106A/mL.
The measurement of plaque: after surface culture dish (1g agarose adds distilled water to 100mL) is dissolved by heating, it is put into 40-50
DEG C water-bath heat preservation, mix with the Hank ' s liquid of equivalent pH7.2-7.4,2 times of concentration, packing small test tube, every pipe 0.5mL, then to pipe
Interior plus 50uL 10%SRBC (v/v, with SA buffer), 20uL splenocyte suspension (5 × 106A/mL), it mixes rapidly, inclines
In on the slide of brush agarose thin layer, parallel plate is done, after agar solidification, slide level is buckled and is placed on horse, is put into
It is incubated for 1.5h in carbon dioxide incubator, is then added in slide rack slot with the diluted complement of SA buffer (1: 8), continues to incubate
After 1.5h, hemolysis plaque number is counted.
(4) measurement of serum hemolysin
Hemagglutination Method.Sheep blood is taken, with brine 3 times, is centrifuged (2000r/min) 10min every time.Hematocrit SRBC is used
Physiological saline is made into the cell suspension of 2% (v/v), and every mouse intraperitoneal injection 0.2mL is immunized.After 4-5 days, extracts eyeball and take
Blood places about 1h in centrifuge tube, and solidification blood and tube wall are removed, serum is precipitated sufficiently, and 2000r/min is centrifuged 10min, receives
Collect serum.
Agglutinating reaction: with physiological saline by serum doubling dilution, the serum of different dilutions is respectively placed in Microhemagglutination
In experimental plate, every hole 100uL adds 100uL 0.5% (v/v) SRBC suspension, mixes, and is put into wet square position and adds
Lid, in 37 DEG C of CO2Incubation 3h observes hemagglutination degree.Go out antibody product according to the level calculation of serum agglutination degree.
(5) mouse carbonic clearance test
Diluted india ink (10mL/kg) is injected from mouse tail vein by weight, is injected to prepared Chinese ink, the injection of timing immediately
2,10min after prepared Chinese ink, takes blood 20uL from angular vein clump respectively, exists side by side and be added into 2mL0.1%Na2CO3In solution.It is each to inhale
0.1mL in 96 hole elisa Plates, with microplate reader at 600nm wavelength densitometric value (OD), with Na2CO3Solution does negative right
According to.
Mouse is put to death, liver and spleen are taken, organ surface blood stains is blotted with filter paper, weighs respectively.
The ability of mouse carbonic clearance is indicated with phagocytic index.Phagocytic index a is calculated as follows, the phagocytosis of test sample group refers to
Number is significantly higher than control group, can determine that this experimental result positive.
(6) peritoneal macrophage phagocytosis chicken red blood cell test
Half intracorporal method.The chicken erythrocyte suspension of preparation 20%, every mouse are injected intraperitoneally the 1mL suspension, put to death after 30min dynamic
Object is faced upward position and is fixed on mouse plate, opens abdomen, through Intraperitoneal injection physiological saline 2mL, rotates mouse plate 1min, then, abdominal cavity is sucked out
Washing lotion 1mL, average mark drop is on 2 glass slides, 37 DEG C of incubation 30min；It educates to finish and be rinsed with physiological saline, dried, with the third of 1: 1
Ketone methanol solution is fixed, and 4%Giemsa- phosphate buffer dyes 3min, then is dried with distilled water rinsing.100 are counted under oil mirror
A macrophage, is calculated as follows phagocytic rate and phagocytic index:
(7) NK cell activity is estimated
Lactic dehydrogenase (LDH) measuring method
The passage (YAC-1 cell) of target cell: target cell is subjected to secondary culture for 24 hours before experiment.With preceding with Hank ' s liquid
It washes 3 times, is 4 × 10 with RPMI1640 complete culture solution adjustment cell concentration5A/mL.
The preparation (effector cell) of splenocyte suspension: it is sterile to take spleen, it is placed in the small plate for filling appropriate sterile Hank ' s liquid
In, gently spleen is ground with tweezers, single cell suspension is made.It through 200 mesh net filtrations, is washed 2 times with Hank ' s liquid, is centrifuged every time
10min(1000r/min).It abandons supernatant to bounce cytoplasm, is added 0.5mL aqua sterilisa 20 seconds, is added after splitting erythrocyte
2 times of Hank ' s liquid of 0.5mL and 8mL Hank ' s liquid, 1000r/min, 10min centrifugation, with 1mL containing 10% calf serum
RPMI1640 complete culture solution is resuspended, and with (viable count should be 95% or more) is counted after the dilution of 1% glacial acetic acid, is contaminated with platform phenol orchid
Color living cell counting number (should be 95% or more) is finally 2 × 10 with RPMI1640 complete culture solution adjustment cell concentration7A/
mL。
NK cytoactive detection: target cell and each 100uL of effector cell (effect target is than 50: 1) are taken, U-shaped 96 hole culture is added
In plate；Target cell Spontaneous release hole adds target cell and each 100uL of culture solution, and target cell maximum relief hole adds target cell and 1%
Each 100uL of NP40；Above-mentioned items are all provided with three parallel holes, in 37 DEG C, 5%CO24h is cultivated in incubator, then cultivates 96 holes
Plate is centrifuged 5min with 1500r/min, and every hole is drawn in 96 well culture plate of supernatant 100uL horizontalization bottom, while LDH matrix liquid is added
100uL, according to room temperature differential responses 3-10min, the HCL 30uL of 1moL/L is added in every hole, and light is measured at microplate reader 490nm
Density value (OD).NK cell activity is calculated by following calculation formula, the NK cell activity of test sample group is significantly higher than control group
NK cell activity, that is, can determine that this experimental result positive.
(8) data processing and result judgement
With SPSS software, one-way analysis of variance method and multiple experimental groups and control group mean compare two-by-two
Method, compares dosage group and whether control group is variant.If difference has significantly any one dosage group compared with the control group
Property and enhancing (p < 0.05), then the experiment be the positive.
Variance analysis is generally used, but need to first carry out homogeneity test of variance by the program of variance analysis, variance is neat, calculates F
Value, F value < F0.05, conclusion: no significant difference between each group mean: F value >=F0.05, P≤0.05, with multiple experimental groups and one
The comparative approach two-by-two of mean is counted between a control group.
Variable conversion appropriate is carried out to the data of abnormal and heterogeneity of variance, after meeting normal state or variance and requiring together,
It is counted with the data after conversion；If being still not up to normal state or the neat purpose of variance after variable conversion, use instead rank sum test into
Row statistics.
Experimental result
(1) to the influence of mouse weight
In five experimental groups, given the test agent all has no significant effect each dosage group mouse weight, compared with negative control group,
There are no significant for difference (being P > 0.05), is as a result shown in Table 1, table 2, table 3, table 4, table 5 respectively.
Influence (mean ± standard deviation) of the table 1 to first group of mouse weight
Note: each dosage group is compared with negative control group, P > 0.05
Influence (mean ± standard deviation) of the table 2 to second group of mouse weight
Note: each dosage group is compared with negative control group, P > 0.05
Influence (mean ± standard deviation) of the table 3 to third group mouse weight
Note: each dosage group is compared with negative control group, P > 0.05
Influence (mean ± standard deviation) of the table 4 to the 4th group of mouse weight
Note: each dosage group is compared with negative control group, P > 0.05
Influence (mean ± standard deviation) of the table 5 to the 5th group of mouse weight
Note: each dosage group is compared with negative control group, P > 0.05
(2) to the influence of mouse lymph organ/weight ratio:
Compared with negative control, animal lymph organ/weight ratio cannot be remarkably reinforced in each dosage group, and P > 0.05 is shown in
Table 6.
Table 6 is to the influence of mouse lymph organ/weight ratio (mean ± standard deviation)
Note: each dosage group is compared with negative control group, P > 0.05
(3) to the influence of mouse spleen lymphocyte conversion
Compared with negative control group, high dose group can enhance the splenic lymphocytes competence for added value of mouse ConA induction, P <
0.05, it is shown in Table 7.
(4) to the influence of mouse delayed allergy
Compared with negative control group, each dosage group cannot enhance mouse and react the DTH that DNFB induces, and P > 0.05 is shown in
Table 7.
Influence (mean ± standard deviation) of the table 7 to cellular immune function
Note: each dosage group is compared with negative control group, P < 0.05
(5) influence to the detection of mouse antibodies cellulation:
Compared with negative control group, high dose group can enhance mouse antibodies cellulation quantity, and P < 0.05 is shown in Table 8.
Influence (mean ± standard deviation) of the table 8 to antibody-producting cell function and hemolysin titre levels
Note: each dosage group is compared with negative control group, P < 0.05
(6) to the influence of mice serum hemolysin titre levels
Compared with negative control group, high dose group can enhance mice serum haemolysis cellulose content, and P < 0.05 is shown in Table 8.
(7) to the influence of mouse carbonic clearance function
Compared with negative control group, middle and high dosage group can improve mouse carbonic clearance phagocytic index, and P < 0.05 is shown in Table 9.
Influence (mean ± standard deviation) of the table 9 to mouse carbonic clearance function
Note: each dosage group is compared with negative control group, P < 0.05
(8) to the influence of Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell
Compared with negative control group, high dose group can improve mouse phagocytic percentage and mouse phagocytic index, P < 0.05,
It is shown in Table 10.
Influence (mean ± standard deviation) of the table 10 to Turnover of Mouse Peritoneal Macrophages immune function
Note: each dosage group is compared with negative control group, P < 0.05
(9) on the active influence of NK cells in mice
Compared with negative control group, each dosage group cannot enhance NK cells in mice activity, and P > 0.05 is shown in Table 11.
Influence (mean ± standard deviation) of the table 11 to Turnover of Mouse Peritoneal Macrophages immune function
Note: each dosage group is compared with negative control group, P > 0.05
Conclusion
It selects SPF grades of Kunming kind female mices as experimental system, has carried out this product strengthen immunity function test.According to
Human body day recommended intake is 75g/ person/days (1.25g/kg BW), designs 12.5g/kg BW, 25g/kg BW, 37.5g/kg
Tri- dosage groups of BW (respectively 10 times, 20 times, 30 times of suitable human body recommended amounts).Negative control group is set simultaneously, animal is continuously given
Start to test after giving 30 days.Experimental result is judged as significant difference with P < 0.05, each dosage group compared with negative control group,
As the result is shown:
(1) each dosage group and mouse weight and lymphoid organ/weight ratio are influenced without conspicuousness；
(2) the spleen lymphocyte proliferation ability of high dose group energy conspicuousness enhancing mouse ConA induction；
(3) each dosage group is unable to the DTH reaction that conspicuousness enhancing mouse induces DNFB；
(4) high dose group energy conspicuousness enhances mouse antibodies cellulation quantity；
(5) high dose group energy conspicuousness enhances mice serum haemolysis cellulose content；
(6) middle and high dosage group can significantly improve mouse carbonic clearance phagocytic index；
(7) high dose group can significantly improve Turnover of Mouse Peritoneal Macrophages percentage phagocytosis and phagocytic index；
(8) NK cells in mice activity cannot be remarkably reinforced in each dosage group.
It is provided according to strengthen immunity function assessment process, in summary every test result determines, the tested material
, the humoral immune function positive negative to mouse cell immune function, one macrophage function of monokaryon is positive, NK cell activity is positive
Property, therefore, it is determined that the given the test agent has strengthen immunity function.
3 weight-reducing experiment of embodiment:
Experimental subjects: 40 obese adult deskmans (based on mental labour) are divided into experimental group and control group,
Each 10 people of every group of men and women.
Experimental method: 6 weeks weight loss programs are formulated.
The 1-2 weeks:
Breakfast: experimental group subject brews 2 marsupial bone collagen peptide combinations with 300 milliliters of warm water and drinks.
Control group subject feeds 250 milliliters of defatted milk, one, egg, steamed stuffed bun one.
Lunch: experimental group subject 15 minutes before the meal, 2 marsupial bone collagen peptide combinations drink is brewed with 300 milliliters of warm water
With.Feed is without 150 grams of starch vegetables, fishes and shrimps or 75 grams of meat products, 75 grams of bean product.
Control group subject feed is without 150 grams of starch vegetables, fishes and shrimps or 75 grams of meat products, and 75 grams of bean product, staple food rice
Meal is fed according to oneself wish.
Dinner: experimental group subject meal brews 2 marsupial bone collagen peptide combinations with 300 milliliters of warm water and drinks.
Control group subject feed is without 150 grams of starch vegetables, fishes and shrimps or 75 grams of meat products, and 75 grams of bean product, staple food rice
Meal is fed according to oneself wish.
The 3-4 weeks
Breakfast: experimental group subject 15 minutes before the meal, 2 marsupial bone collagen peptide combinations drink is brewed with 300 milliliters of warm water
With.250 milliliters of defatted milk, one, egg, steamed stuffed bun one of feed.
Control group subject feeds 250 milliliters of defatted milk, one, egg, steamed stuffed bun one.
Lunch: experimental group subject 15 minutes before the meal, 2 marsupial bone collagen peptide combinations drink is brewed with 300 milliliters of warm water
With.Feed is without 150 grams of starch vegetables, fishes and shrimps or 75 grams of meat products, 75 grams of bean product.
Control group subject feed is without 150 grams of starch vegetables, fishes and shrimps or 75 grams of meat products, and 75 grams of bean product, staple food rice
Meal is fed according to oneself wish.
Dinner: experimental group subject's dinner is not fed.
Control group subject feed is without 150 grams of starch vegetables, fishes and shrimps or 75 grams of meat products, and 75 grams of bean product, staple food rice
Meal is fed according to oneself wish.
The 5-6 weeks
Breakfast: experimental group subject 15 minutes before the meal, 2 marsupial bone collagen peptide combinations drink is brewed with 300 milliliters of warm water
With.250 milliliters of defatted milk, one, egg, steamed stuffed bun one of feed.
Control group subject feeds 250 milliliters of defatted milk, one, egg, steamed stuffed bun one.
Lunch: experimental group subject 15 minutes before the meal, 1 marsupial bone collagen peptide combinations drink is brewed with 300 milliliters of warm water
With.150 grams of vegetables of feed, fishes and shrimps or 75 grams of meat products, 75 grams of bean product, staple food rice is fed according to oneself wish.
Control group subject feeds 150 grams of vegetables, and fishes and shrimps or 75 grams of meat products, 75 grams of bean product, staple food rice is according to oneself
Own wish feed.
Dinner: experimental group subject's dinner is not fed.
Control group subject feeds 150 grams of vegetables, and fishes and shrimps or 75 grams of meat products, 75 grams of bean product, staple food rice is according to oneself
Own wish feed.
Whole day fruit intake be no more than 200g, 2400--3000 milliliters of drinking water.
Experiment instrument: scale
Experimental result:
By 42 days confirmatory experiments, control group weight and body fat rate did not change；Experimental group subject's average weight subtracts
6 kilograms light, body fat rate averagely declines 5.0 percentage points.The volunteer for participating in loss of weight reacts, during this, without obvious hungry
Feel, feeling relaxed after loss of weight, no sense of discomfort, constitution is not influenced by loss of weight, and work and life quality is guaranteed.Experimental result is such as
Shown in following table:
By table as it can be seen that weight-reducing fat reducing product of the invention adds simultaneously using bone collagen peptide and PURE WHEY as raw material
Add probiotics, prebiotics, vitamin and a variety of mineral elements, so that this product is meeting needed by human body heat and basic nutrition member
While plain, have effects that significantly weight-reducing and fat reducing, is suitable for obese people and uses.
Claims (2)
1. a kind of bone collagen compound powder, which is characterized in that the weight percent of each component is as follows: bone collagen Gly-His-Lys
16%, PURE WHEY 16%, skimmed milk powder 12.8%, vegetable fat powder 16%, D-sorbite 8%, inulin 10%, oligofructose
4.844%, calcium monohydrogen phosphate 3.824%, instant black tea 1.68%, xylo-oligosaccharide 0.8%, Cranberry powder 0.8%, blueberry powder
0.8%, blackberry powder 0.8%, raspberry powder 0.8%, cherry powder 0.8%, honey peach powder 0.8%, blackcurrant powder 0.8%, Kiwi berry
Powder 0.8%, shaddock powder 0.8%, orange powder 0.8%, essence for food 1.2%, γ-aminobutyric acid 0.3%, L-AA sodium
0.246%, bacillus coagulans 0.2%, zinc gluconate 0.044%, ferric citrate 0.046%, niacin 0.011%, general
Sour 0.0022%, vitamin B10.001%, vitamin B20.001%, vitamin B60.0008%, vitamin D
0.000002%.
2. bone collagen peptide combinations according to claim 1 the preparation method is as follows:
(1) by oligofructose, calcium monohydrogen phosphate, instant black tea, xylo-oligosaccharide, Cranberry powder, blueberry powder, blackberry powder, raspberry powder, cherry
Peach powder, honey peach powder, blackcurrant powder, kiwi fruit powder, shaddock powder, orange powder, essence for food, γ-aminobutyric acid, L- Vitamin C
Sour sodium, zinc gluconate, ferric citrate, bacillus coagulans, niacin, pantothenic acid (D-VB5 calcium), vitamin B1, vitamin
B2, vitamin B6, vitamin D mix to obtain mixed powder 1；
(2) bone collagen Gly-His-Lys, PURE WHEY, skimmed milk powder, vegetable fat powder, D-sorbite, inulin mixing, obtain mixed powder 2；
(3) above-mentioned mixed powder 1,2 is mixed, be uniformly mixed to get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810464630.2A CN109077326A (en) | 2018-05-10 | 2018-05-10 | A kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810464630.2A CN109077326A (en) | 2018-05-10 | 2018-05-10 | A kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109077326A true CN109077326A (en) | 2018-12-25 |
Family
ID=64839644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810464630.2A Pending CN109077326A (en) | 2018-05-10 | 2018-05-10 | A kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109077326A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112715931A (en) * | 2021-01-15 | 2021-04-30 | 北京同仁堂健康药业股份有限公司 | Composition with antiviral and immunity improving effects and preparation method and application thereof |
| CN112841660A (en) * | 2021-02-04 | 2021-05-28 | 海南华研胶原科技股份有限公司 | Collagen peptide composition with immunity enhancing and fatigue resisting functions |
| WO2024153892A1 (en) * | 2023-01-20 | 2024-07-25 | Kurdyk Bernard Jacques | Oral hygiene composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876585A (en) * | 2016-04-29 | 2016-08-24 | 周姝 | Protein solid beverage and preparation method and application thereof |
| CN107927510A (en) * | 2017-11-28 | 2018-04-20 | 天津活力达生物科技有限公司 | A kind of collagen solid beverage and preparation method thereof |
| CN107950851A (en) * | 2017-11-13 | 2018-04-24 | 江苏大学 | One kind is without bitter taste complex polypeptide powder |
-
2018
- 2018-05-10 CN CN201810464630.2A patent/CN109077326A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876585A (en) * | 2016-04-29 | 2016-08-24 | 周姝 | Protein solid beverage and preparation method and application thereof |
| CN107950851A (en) * | 2017-11-13 | 2018-04-24 | 江苏大学 | One kind is without bitter taste complex polypeptide powder |
| CN107927510A (en) * | 2017-11-28 | 2018-04-20 | 天津活力达生物科技有限公司 | A kind of collagen solid beverage and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 仲山民主编: "《食品营养学》", 30 August 2017, 华中科技大学出版社 * |
| 池肇春等主编: "《消化系统疾病鉴别诊断与治疗学》", 31 July 2017, 山东科学技术出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112715931A (en) * | 2021-01-15 | 2021-04-30 | 北京同仁堂健康药业股份有限公司 | Composition with antiviral and immunity improving effects and preparation method and application thereof |
| CN112841660A (en) * | 2021-02-04 | 2021-05-28 | 海南华研胶原科技股份有限公司 | Collagen peptide composition with immunity enhancing and fatigue resisting functions |
| WO2024153892A1 (en) * | 2023-01-20 | 2024-07-25 | Kurdyk Bernard Jacques | Oral hygiene composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neumann et al. | Contribution of animal source foods in improving diet quality and function in children in the developing world | |
| Hsia et al. | A one-year, controlled study of the effect of low-phenylalanine diet on phenylketonuria | |
| Mudambi | Fundamentals of foods, nutrition and diet therapy | |
| CN109430413A (en) | A kind of composition of strengthen immunity, functional food and preparation method thereof | |
| CN107136509A (en) | It is a kind of to be used to improve functional food of immunity and preparation method thereof | |
| TR201807483T4 (en) | A composition comprising specific strains of lactobacilli helveticus and reducing the symptoms of food and / or respiratory allergy. | |
| CN109077326A (en) | A kind of bone collagen peptide combinations with strengthen immunity and effect of weight reducing | |
| CN107348483A (en) | A kind of pregnant and lying-in women's full function nutritious supplementary pharmaceutical | |
| CN101574151A (en) | Nutritional food with function of strengthening immunity and preparation method thereof | |
| CN103735556B (en) | A kind of multi-vitamin mineral composite effervescent sheet and preparation method | |
| Neumann et al. | Contribution of animal source foods in improving diet quality for children in the developing world | |
| CN101336661A (en) | Nonspecific compound polysaccharide immune milk and preparation method thereof | |
| CN100422309C (en) | Use of plant lactobacillus ST-III in fat-reduction | |
| CN109419003A (en) | Breast milk oligosaccharide is preparing the purposes in food or drug | |
| CN103478443A (en) | Micro-ecological preparation and application thereof in improvement of production performance, immune performance as well as chicken quality of broiler | |
| CN108935701A (en) | A kind of preparation method and application improving the goat milk powder of immunity, goat milk powder | |
| CN105192698B (en) | A kind of health food containing leaf of Moringa powder and preparation method thereof | |
| CN103976216A (en) | Health-protection product with functions of supplementing calcium and enhancing immunity and preparation method for health-protection product | |
| CN109287747A (en) | A kind of preparation method of colostrum element | |
| Khosla | 4Gs Of Good Health: Don't Diet, Know What's Right for Your Body | |
| Abul-fadl et al. | How Breastfeeding & Complementary Feeding Practices affect Nutritional Status of Young Children in Egypt | |
| Sanou et al. | Impact of an integrated nutrition intervention on nutrient intakes, morbidity and growth of rural Burkinabe preschool children | |
| Vance | The Perfect Metabolism Plan: Restore Your Energy and Reach Your Ideal Weight | |
| Muktamath et al. | Breastfeeding Practices and Infant Development Outcomes | |
| Amin | Effect of Maternal and Child Diet on Childhood Undernutrition in Rural Bangladesh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181225 |